{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse:00297:a retrieved successfully",
    "request_url": "https://api.moalmanac.org/indications?indication_id=ind%3Ahse%3A00297%3Aa",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001588,
    "timestamp_received": "2026-11-09T16:14:15.096528Z",
    "timestamp_returned": "2026-11-09T16:14:15.098116Z",
    "trace_id": "d492538e-9191-47d5-9196-84be034e2101"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-10-08"
  },
  "data": [
    {
      "id": "ind:hse:00297:a",
      "type": "Indication",
      "description": "As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2026-08-02:0",
          "type": "Contribution",
          "description": "Initial curation of into moalmanac-db",
          "date": "2026-08-02",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:hse:2026-07-29:0",
          "type": "Contribution",
          "description": "Indication approved for reimbursement.",
          "date": "2026-07-29",
          "contributor": {
            "id": "agent:org:hse",
            "type": "Agent",
            "agentType": "organization",
            "name": "Health Service Executive",
            "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:hse:00297",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Ibrutinib Therapy - Mantle Cell Lymphoma. NCCP National SACT Regimen. HSE.",
          "title": null,
          "aliases": [],
          "description": "Ibrutinib Therapy - Mantle Cell Lymphoma, 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6953/297_Ibrutinib_MCL.pdf",
          "urls": [
            "https://healthservice.hse.ie/documents/6953/297_Ibrutinib_MCL.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:hse",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Service Executive",
                "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": null,
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": null,
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2016-07-29",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "publication_date",
              "value": "2022-11-28",
              "description": "The publication date for the document."
            },
            {
              "name": "regulatory_identifier",
              "value": null,
              "description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        },
        {
          "name": "statement description",
          "value": "The Republic of Ireland's Health Service Executive (HSE) has approved ibrutinib for reimbursement as a single agent treatment option for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. The treatment regimen further describes the eligibility criteria as requiring cyclin D1 overexpression or translocation breakpoints at t(11;14).",
          "description": "The description text for all Statements derived from this Indication."
        },
        {
          "name": "reimbursement_scheme",
          "value": "CDS",
          "description": "Current scheme used to reimburse indication."
        },
        {
          "name": "reimbursement_comment",
          "value": null,
          "description": "More details about the current reimbursement scheme(s)."
        }
      ]
    }
  ]
}